- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 100 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 41 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 135 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 221 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB Q3 Loss Decreases | 2 | RTTNews | ||
| 26.11.25 | Immunovia: Strategiewechsel und Aktiensprung nach Q3-Zahlen | 3 | Investing.com Deutsch | ||
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 195 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 179 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen | |
| 03.10.25 | Immunovia AB: Immunovia publishes information document regarding rights issue | 449 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 01.10.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.10.2025 | 559 | Xetra Newsboard | Das Instrument RIHN CH0003671440 RIETER HLDG NA SF 5 EQUITY wird cum Kapitalmassnahme gehandelt am 01.10.2025 und ex Kapitalmassnahme am 02.10.2025 The instrument RIHN CH0003671440 RIETER HLDG NA SF... ► Artikel lesen | |
| 29.09.25 | Immunovia AB: Bulletin from the extraordinary general meeting in Immunovia AB (publ) | 296 | GlobeNewswire (Europe) | Today, on 29 September 2025, an extraordinary general meeting was held in Immunovia AB (publ). A summary of the adopted resolutions follows below.
Resolution on amendment of the Articles of AssociationThe... ► Artikel lesen | |
| 23.09.25 | Proteomedix vereinbart Lizenzabkommen mit Immunovia | 2 | punkt4.info | ||
| 22.09.25 | Onconetix-Tochter lizenziert Biomarker-Technologie an Immunovia | 1 | Investing.com Deutsch | ||
| 22.09.25 | Onconetix, Inc.: Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM | 534 | GlobeNewswire (Europe) | CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization... ► Artikel lesen | |
| 22.09.25 | Immunovia AB: Immunovia Secures Control of PancreaSure Supply Chain and Achieves Cost Reduction through Licensing Agreement | 222 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia AB (publ.), the pancreatic cancer diagnostics company, has announced the successful conclusion of an agreement to acquire assets and license intellectual property that will... ► Artikel lesen | |
| 15.09.25 | Immunovia AB: Inova Schar Cancer Adopts Immunovia's PancreaSure Test for its High-Risk Surveillance Program | 227 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its PancreaSure test will be offered to patients in Inova Schar Cancer's high-risk surveillance program... ► Artikel lesen | |
| 08.09.25 | Immunovia AB: Immunovia enters into top guarantee commitments for the upcoming rights issue | 255 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 28.08.25 | Immunovia AB: Immunovia Publishes Interim Report for January-June 2024 | 210 | GlobeNewswire (Europe) | April-June 2025Net sales, which for the quarter only included royalties, amounted to 90 KSEK (85).Operating loss was -20.1 MSEK, down from -23.9 MSEK in the second quarter of 2024. Net earnings were... ► Artikel lesen | |
| 27.08.25 | Immunovia AB: Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans | 489 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 19.08.25 | Immunovia AB: Immunovia set to launch PancreaSure in the US on September 2nd, shares commercial strategy | 200 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (publ.) the pancreatic cancer diagnostics company, today announced that the PancreaSure test is set to launch in the US on September 2nd. The company's initial focus will be... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 12,285 | +0,08 % | Marge kollabiert: Hims stürzt nach Prognose ab - Novo Nordisk bleibt der Brandbeschleuniger | © Foto: Thomas Fuller - SOPA Images via ZUMA Press WireTrotz starker Q4-Zahlen reißt der neue Ausblick ein Loch in die Story. Hohe Ausgaben, ein schwaches erstes Quartal und der Novo-Konflikt setzen... ► Artikel lesen | |
| BECTON DICKINSON | 150,30 | +0,64 % | BD (Becton, Dickinson and Company): Becton, Dickinson and Company Announces Pricing of the Tender Offers and Amounts Accepted for Purchase | FRANKLIN LAKES, N.J., Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the "Company" or "BD"), a leading global medical technology... ► Artikel lesen | |
| RYMAN HEALTHCARE | 1,219 | +0,41 % | RYMAN HEALTHCARE LIMITED: SPH Notice - Cooper Investors Pty Limited | ||
| SOLENO THERAPEUTICS | 31,300 | -4,40 % | Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT XR | REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases... ► Artikel lesen | |
| SIENNA SENIOR LIVING | 14,600 | +1,39 % | Dividendenbekanntmachungen (27.02.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACNB CORPORATION US0008681092 0,38 USD 0,322 EUR AGNC INVESTMENT CORP US00123Q1040 0,12 USD 0,1017 EUR AGREE REALTY CORPORATION US0084921008 0... ► Artikel lesen | |
| NIAGEN BIOSCIENCE | 4,320 | +0,93 % | Niagen Bioscience veräußert Referenzstandard-Geschäft an LGC | ||
| MICROPORT SCIENTIFIC | 1,160 | +1,75 % | MICROPORT (00853): UNAUDITED FINANCIAL INFORMATION OF SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD. FOR THE TWELVE MONTHS ENDED 31 DECEMBER ... | ||
| EXTENDICARE | 14,800 | 0,00 % | Extendicare Inc.: Extendicare Announces 2025 Fourth Quarter and Full Year Results and Dividend Increase | MARKHAM, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) today reported results for the three and twelve months ended December 31, 2025. Fourth... ► Artikel lesen | |
| VERADIGM | 7,350 | -100,00 % | Veradigm avoids enforcement action following SEC investigation | ||
| NATIONAL HEALTHCARE CORPORATION | 133,00 | 0,00 % | NATIONAL HEALTHCARE CORP - 8-K, Current Report | ||
| UNIPHAR | 4,130 | -1,31 % | Uniphar reports double-digit earnings growth | ||
| HANGZHOU TIGERMED CONSULTING | 4,980 | -1,39 % | Tigermed Selected as "2025 Forbes China Go-International Flagship Brands" Top 30 | HANGZHOU, China, Nov. 6, 2025 /PRNewswire/ -- Tigermed has been selected as one of the Top 30 companies on the "2025 Forbes China Go-International Flagship Brands" list, Forbes China... ► Artikel lesen | |
| FRESENIUS | 50,90 | -0,82 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius-Aufsichtsrat verlängert Vertrag des Vorstandsvorsitzenden Michael Sen vorzeitig um 5 Jahre --- Christian Pawlu zum 1. Juli für Fresenius Helios in den Vorstand berufen | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Personalie
Fresenius-Aufsichtsrat verlängert Vertrag des Vorstandsvorsitzenden Michael Sen vorzeitig um 5 Jahre --- Christian... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 42,140 | -0,59 % | RBC stuft Siemens Healthineers auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat Siemens Healthineers mit einem Kursziel von 55 Euro auf "Outperform" belassen. Die Nervosität der Anleger vor einem möglichen Verkauf des Diagnostikgeschäfts... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,220 | -5,83 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,003 (+3.000 %) liegt der Kurs bei 0,003 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.